### eTables:

eTable 1. Table of excluded studies with reasons for exclusion.

eTable 2. Pooled rates with corresponding 95%CI (confidence intervals) of safety and efficacy

outcomes among acute ischemic stroke patients treated with endovascular therapy (EVT) and

best medical treatment (BMT) compared to BMT alone.

### eReferences used in the Supplement.

eFigures:

eFigures 1-23

eTable 1. Table of excluded studies with reasons for exclusion.

Study Name	Reason(s) for Exclusion
Roman et al. <sup>1</sup>	Individual patient data meta-analysis
Hill et al. <sup>2</sup>	Subgroup analysis of Interventional Management of Stroke
	(IMS)-III Trial, with ASPECTS-range of 0-4

**eTable 2.** Pooled rates, risk differences with corresponding 95%CI (confidence intervals), and numbers needed to treat (or harm) of safety and efficacy outcomes among acute ischemic stroke patients treated with endovascular therapy (EVT) and best medical treatment (BMT) compared

to BMT alone.

The corresponding pooled proportions with 95% confidence intervals (95%CI) were calculated after the implementation of the variance-stabilizing double arcsine transformation, as previously described.<sup>3</sup>


Outcomes	mRS 0-3*	mRS 0-2*	mRS 0-1*	sICH	Any ICH	Mortality*
EVT+ BMT	37 (29-45)	20 (13-28)	8 (5-12)	4 (1-9)	42 (11-78)	28 (19-38)
(95%CI)						
BMT	21 (13-30)	9 (7-11)	5 (1-10)	2 (1-4)	19 (5-40)	29 (20-40)
(95%CI)						
RD%(95%CI)	15 (10-20)	11 (5-17)	3 (1-6)	2 (-1 – 4)	23 (3 – 44)	-1 (-5-4)
NNT	7	9	33	50 (NNH)	4 (NNH)	100

\*At three months; mRS: modified Rankin Scale; sICH: symptomatic intracranial hemorrhage; ICH: intracranial hemorrhage; RD: risk difference; NNT: number needed to treat; NNH: number needed to harm.

#### eReferences used in the Supplement.

- 1. Román LS, Menon BK, Blasco J, et al. Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data. Lancet Neurol. 2018;17(10):895-904.
- 2. Hill MD, Demchuk AM, Goyal M, et al. Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial. Stroke. 2014;45(2):444-449.
- 3. Safouris A, Palaiodimou L, Szikora I, et al. Endovascular treatment for anterior circulation largevessel occlusion ischemic stroke with low ASPECTS: a systematic review and meta-analysis. Ther Adv Neurol Disord. 2022;15:17562864221139632.
- 4. McGrath S, Sohn H, Steele R, Benedetti A. Meta-analysis of the difference of medians. 2020;62(1):69-98.
- 5. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:14898.
- 6. Zaidat OO, Yoo A, on behalf of TESLA Investigators (2023, May 26). TESLA Trial: Primary Results. [Conference presentation]. European Stroke Organisation Conference 2023, Munich, Germany.
- 7. Zaidat OO, Kasab SA, Sheth S, et al. TESLA Trial: Rationale, Protocol, and Design. Stroke: Vascular and Interventional Neurology. 2023;0(0):e000787.
- 8. Huo X, Ma G, Tong X, et al. Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct. N Engl J Med. 2023;388(14):1272-1283.
- Sarraj A, Hassan AE, Abraham MG, et al. Trial of Endovascular Thrombectomy for Large Ischemic 9. Strokes. N Engl J Med. 2023;388(14):1259-1271.
- 10. Yoshimura S, Sakai N, Yamagami H, et al. Endovascular Therapy for Acute Stroke with a Large Ischemic Region. N Engl J Med. 2022;386(14):1303-1313.
- 11. von Kummer R, Broderick JP, Campbell BC, et al. The Heidelberg Bleeding Classification: Classification of Bleeding Events After Ischemic Stroke and Reperfusion Therapy. Stroke. 2015 Oct;46(10):2981-6. doi: 10.1161/STROKEAHA.115.010049. Epub 2015 Sep 1.
- 12. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275-282.

### eFigure 1. PRISMA flowchart presenting the selection of eligible studies.



**eFigure 2.** Forest plots presenting the pooled mean of age (in years) of the patients enrolled in the EVT arm (panel A), the pooled mean of age (in years) of the patients enrolled in the BMT arm (panel B), and the mean difference of age (in years) among the patients in the EVT versus the BMT arm (panel C).

SD: standard deviation; CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment.

## Α.

Study	Mean	SD	Total	Weight	Mean IV, Random, 95% CI	Mean IV, Random, 95% Cl
ANGEL-ASPECT	66.70	9.10	230	25.6%	66.70 [65.52, 67.88]	
<b>RESCUE-Japan LIMIT</b>	76.60	10.00	101	24.9%	76.60 [74.65, 78.55]	
SELECT2	67.20	12.90	178	25.0%	67.20 [65.30, 69.10]	
TESLA	64.20	14.60	152	24.5%	64.20 [61.88, 66.52]	
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 23	170.0	.2 _ 00			68.68 [63.84, 73.52]	
Heterogeneity: Tau = 23	3.470; C	$n_1 = 89$	.97, df	= 3 (P < .(	(1); 1 = 97%	65 70 75
						65 70 75 Mean Age
В.						
					Mean	Mean
Study	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
,						
ANGEL-ASPECT	65.70	10.50	225	25.4%	65.70 [64.33, 67.07]	
ANGEL-ASPECT	75.70		102	24.8%	75.70 [73.72, 77.68]	
ANGEL-ASPECT RESCUE-Japan LIMIT	75.70 66.00	10.20	102 173	24.8% 24.9%	75.70 [73.72, 77.68]	* *
ANGEL-ASPECT RESCUE-Japan LIMIT SELECT2 TESLA	75.70 66.00	10.20	102 173 148	24.8% 24.9% 24.9%	75.70 [73.72, 77.68] 66.00 [64.12, 67.88] 65.50 [63.58, 67.42]	-#- -#-
ANGEL-ASPECT RESCUE-Japan LIMIT SELECT2	75.70 66.00 65.50	10.20 12.60 11.90	102 173 148 648	24.8% 24.9% 24.9% <b>100.0%</b>	75.70 [73.72, 77.68] 66.00 [64.12, 67.88] 65.50 [63.58, 67.42] 68.20 [63.68, 72.73]	

# C.

	E	T		BM	Т			Mean Difference		Mea	n Diff	erence		
Study	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	I.	IV, Ra	andom	, 95% (	CI	
ANGEL-ASPECT	66.70	9.10	230	65.70	10.50	225	44.6%	1.00 [-0.81, 2.81]				-		
RESCUE-Japan LIMIT	76.60	10.00	101	75.70	10.20	102	18.9%	0.90 [-1.88, 3.68]				-		
SELECT2	67.20	12.90	178	66.00	12.60	173	20.5%	1.20 [-1.47, 3.87]		-	_			
TESLA	64.20	14.60	152	65.50	11.90	148	16.1%	-1.30 [-4.31, 1.71]	_					
Total (95% CI)			661			648	100.0%	0.65 [-0.55, 1.86]			-			
Heterogeneity: Tau <sup>2</sup> = 0;	Chi <sup>2</sup> =	1.95. df	= 3 (P =	= 58): 12	= 0%					1			1	_
Test for overall effect: Z									-4	-2	0	:	2	4
										Favors E	EVT I	Favors	BMT	

Mean Age

**eFigure 3.** Forest plots presenting the pooled proportion of men among the patients enrolled in the EVT arm (panel A), the pooled proportion of men among the patients enrolled in the BMT arm (panel B), and the odds ratio of men in the EVT versus the BMT arm (panel C).

CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment.

## Α.

Study	Events	Total	Weight	IV, Random, 95% CI	IV	, Ran	dom, 9	95% 0	:1
ANGEL-ASPECT	135	230	31.8%	0.59 [0.52, 0.65]				-	
<b>RESCUE-Japan LIMIT</b>	55	101	17.5%	0.54 [0.44, 0.64]			-		_
SELECT2	107	178	26.8%	0.60 [0.53, 0.67]			-	-	
TESLA	76	152	23.9%	0.50 [0.42, 0.58]	3			-	
Total (95% CI)		661	100.0%	0.56 [0.52, 0.61]		3		<b>.</b>	
Heterogeneity: Tau <sup>2</sup> < 0.	001; Chi <sup>2</sup>	= 4.16	df = 3 (P	$= .24$ ); $l^2 = 28\%$				1	
		- Possene		and and the second second	0.45	0.5	0.55	0.6	0.65
							Males		
р									

#### Β.


Study	Events	Total	Weight	IV, Random, 95% CI	IV	, Rand	om, 98	5% CI	
ANGEL-ASPECT	144	225	34.7%	0.64 [0.57, 0.70]		6	_		_
<b>RESCUE-Japan LIMIT</b>	58	102	15.7%	0.57 [0.47, 0.67]					
SELECT2	100	174	26.8%	0.57 [0.50, 0.65]					
TESLA	84	148	22.8%	0.57 [0.48, 0.65]	10			-	
Total (95% CI)			100.0%		12.2	_	_		
Heterogeneity: Tau <sup>2</sup> = 0;	$Chi^2 = 2.$	98, df =	3 (P = .4	0); $l^2 = 0\%$	E.	1	3	1	- 2
			2		0.5	0.55	0.6	0.65	0.7
						M	ales		

# C.

	E	T	B	TN		Odds Ratio		Odds Ratio	
Study	Events	Total	Events	Total	Weight	IV, Random, 95% (		IV, Random, 95% CI	
ANGEL-ASPECT	135	230	144	225	33.9%	0.80 [0.55, 1.17]	7		
<b>RESCUE-Japan LIMIT</b>	55	101	58	102	15.8%	0.91 [0.52, 1.58]			
SELECT2	107	178	100	174	26.9%	1.12 [0.73, 1.71]			<u></u>
TESLA	76	152	84	148	23.4%	0.76 [0.48, 1.20]	7 <u></u>		
Total (95% CI)		661		649	100.0%	0.88 [0.71, 1.10]	_		
Heterogeneity: Tau <sup>2</sup> = 0	; Chi <sup>2</sup> = 1	.84, df =	= 3 (P = .6	$(1);  ^2 =$	0%				1
Test for overall effect: Z	= -1.12 (F	P = .26)					0.5	1	2
								Favors BMT Favors EVT Males	<i>v</i>

**eFigure 4.** Forest plots presenting the pooled median of NIHSS of the patients enrolled in the EVT arm (panel A), the pooled median of NIHSS of the patients enrolled in the BMT arm (panel B), and the difference of medians of NIHSS among the patients in the EVT versus the BMT arm (panel C), as calculated by the quantile estimation (QE) method.<sup>4</sup>

CI: confidence interval; RE: random effect; NIHSS: National Institutes of Health Stroke Scale.




**eFigure 5.** Forest plots presenting the pooled median of ASPECTS of the patients enrolled in the EVT arm (panel A), the pooled median of ASPECTS of the patients enrolled in the BMT arm (panel B), and the difference of medians of ASPECTS among the patients in the EVT versus the BMT arm (panel C), as calculated by the quantile estimation (QE) method.<sup>4</sup>

CI: confidence interval; RE: random effect; ASPECTS: Alberta Stroke Program Early CT Score.

Α.		Median (95%CI)
ANGEL-ASPECT	-	3.00 [2.87, 3.13]
RESCUE-Japan LIMIT	-	3.00 [2.81, 3.19]
SELECT2	·•	4.00 [3.73, 4.27]
TESLA	<b>•</b>	4.00 [3.70, 4.30]
RE Model Heterogeneity: df=3; l <sup>2</sup> = 96%; p<0.01	35 4 45	3 49 (2 97, 4.00)
В.		Median (95%CI)
ANGEL-ASPECT		3.00 [2.87, 3.13]
RESCUE-Japan LIMIT	an a	3.00 [2.81, 3.19]
SELECT2	<b></b>	4,00 [3.86, 4.14]
TESLA	·	4 00 [3.70, 4.30]
RE Model Heterogeneity: df=3; 1 <sup>2</sup> = 98%; p<0.01	_	3.49 [2.91, 4.08]
2.5 3 Poole	3.5 4 4.5 ed Median of ASPECTS	
С.	E.	Median (95%CI)
ANGEL-ASPECT	F	0.00 [-0.18, 0.18]
RESCUE-Japan LIMIT		0.00 [-0.27, 0.27]
SELECT2		0.00 [-0.31, 0.31]
TESLA		0.00 [-0.42, 0.42]
RE Model Heterogeneity: df=3; l <sup>2</sup> = 0%; p=0.65 Test for overall effect: Z= 1.65 (p=0.10)		0.00 [-0.13, 0.13]
	0.2 0 0.2 0.4 0.6 nce of Medians of ASPECTS	

**eFigure 6.** Forest plots presenting the pooled median of ischemic-core volume (in ml) of the patients enrolled in the EVT arm (panel A), the pooled median of ischemic-core volume (in ml) of the patients enrolled in the BMT arm (panel B), and the difference of medians of ischemic-core volume (in ml) among the patients in the EVT versus the BMT arm (panel C), as calculated by the quantile estimation (QE) method.<sup>4</sup>

CI: confidence interval; RE: random effect.



**eFigure 7.** Forest plots presenting the pooled proportion of IVT pretreatment among the patients enrolled in the EVT arm (panel A), the pooled proportion of IVT pretreatment among the patients enrolled in the BMT arm (panel B), and the odds ratio of IVT pretreatment in the EVT versus the BMT arm (panel C).


CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment; IVT: intravenous thrombolysis.

Otrada	Evente	Tetal	Mainha	N/ Dandam OF0/ (		and any OFO/ CI
Study	Events	Iotal	weight	IV, Random, 95% (	I IV, Ra	andom, 95% Cl
ANGEL-ASPECT	66	230	30.4%	0.29 [0.23, 0.35]		
<b>RESCUE-Japan LIMIT</b>	27	101	18.7%	0.27 [0.18, 0.36]	1.5	
SELECT2	37	178	26.6%	0.21 [0.15, 0.27]		
TESLA	31	152	24.3%	0.20 [0.14, 0.28]	-	
Total (95% CI)			100.0%			
Heterogeneity: Tau <sup>2</sup> = 0.	001; Chi <sup>2</sup>	= 5.20,	df = 3 (P :	= .16); I <sup>2</sup> = 42%	I I	
					0.15 0.2	0.25 0.3 0.35 IVT
B.						
Study	Events	Total	Weight	IV, Random, 95%	CI IV, R	andom, 95% Cl
ANGEL-ASPECT	63	225	28.1%	0.28 [0.22, 0.34]	1	
<b>RESCUE-Japan LIMIT</b>	29	102	21.2%	0.28 [0.20, 0.38]	-	
SELECT2	30	173	26.0%	0.17 [0.12, 0.24]		
TESLA	30	148	24.7%	0.20 [0.14, 0.28]	-	
Total (95% CI)			100.0%			
Heterogeneity: Tau <sup>2</sup> = 0.	003; Chi <sup>2</sup>	= 8.63	df = 3 (P	= .03); 1 <sup>2</sup> = 65%	1 1	
					0.15 0.3	2 0.25 0.3 0.35 IVT
					D. //	
С.	EVE		DAAT			
	EVT		BMT	al Weight IV, Rando	s Ratio	Odds Ratio IV, Random, 95%


Study	Events	Total	Events	Total	Weight	IV, Random, 95% C	1	IV, Random, 95% C	1
ANGEL-ASPECT	66	230	63	225	39.3%	1.03 [0.69, 1.56]			-
<b>RESCUE-Japan LIMIT</b>	27	101	29	102	17.2%	0.92 [0.50, 1.70]	-		
SELECT2	37	178	30	173	22.8%	1.25 [0.73, 2.14]			
TESLA	31	152	30	148	20.7%	1.01 [0.57, 1.77]			
Total (95% CI)		661			100.0%	1.05 [0.82, 1.36]	_		
Heterogeneity: Tau <sup>2</sup> = 0	Chi <sup>2</sup> = 0.	.62, df =	: 3 (P = .8	(9); $I^2 =$	0%		1	1	1
Test for overall effect: Z	= 0.40 (P	= .69)					0.5	1	2
								Favors BMT Favors E	VT

**eFigure 8.** Forest plots presenting the pooled median time onset-to-randomization (in minutes) of the patients enrolled in the EVT arm (panel A), the pooled median time onset-to-randomization (in minutes) of the patients enrolled in the BMT arm (panel B), and the difference of medians of time onset-to-randomization (in minutes) among the patients in the EVT versus the BMT arm (panel C), as calculated by the quantile estimation (QE) method.<sup>4</sup>

CI: confidence interval; RE: random effect.



**eFigure 9.** Summary plot presenting the quality assessment of included randomized controlled clinical trials using the Cochrane Collaboration tool (RoB 2).<sup>5</sup>



All of the studies were free of risk of bias in two domains: the measurement of outcomes (since all adjudicators were blinded to the patients' allocation) and the results' reporting. The TESLA<sup>6,7</sup> trial presented minor concerns in the randomization process due to the inclusion of more patients with diabetes mellitus in the interventional arm compared to control. Furthermore, due to the nature of the intervention, blinding of participants and investigators was not possible in any of the included trials. Additionally, in ANGEL-ASPECT,<sup>8</sup> SELECT2,<sup>9</sup> and TESLA<sup>6,7</sup> trials, minor deviations from intended interventions were noted; such a bias was not detected in RESCUE-Japan LIMIT<sup>10</sup> trial. Finally, in SELECT2<sup>9</sup> and TESLA<sup>6,7</sup> trials, there were minor concerns due to missing data regarding outcomes (due to lost to follow up patients).

**eFigure 10.** Traffic Light Plot presenting the quality assessment of included randomized controlled clinical trials using the Cochrane Collaboration tool (RoB 2).<sup>5</sup>

				Risk of bia	s domains		
		D1	D2	D3	D4	D5	Overall
	ANGEL-ASPECT	+	-	+	+	+	-
Study	RESCUE-Japan LIMIT	+	-	+	+	+	-
Sti	SELECT2	+	-	-	+	+	-
	TESLA	-	-	-	+	+	-
		D2: Bias du D3: Bias du D4: Bias in	e to deviatior e to missing measuremen	randomizations from intence outcome data t of the outcome reported re	led interventi ı. me.	011.	ment Some concerns ow

eFigure 11: Sensitivity analysis regarding the association of EVT compared to BMT with reduced disability at 3 months, using the generalized OR as reported by 2 studies.<sup>8,9</sup>


SE: standard error; CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment.

Study	logOR	SE V	Veight	Odds Ratio IV, Random, 95% Cl		ds Ratio dom, 95	
ANGEL-ASPECT	0.31 C	D.11	54.3%	1.36 [1.10, 1.69]			-
SELECT2	0.41 0	0.12	45.7%	1.51 [1.19, 1.91]		-	
Total (95% CI)			00.0%	1.43 [1.22, 1.67]			
Heterogeneity: Tau <sup>2</sup>				° = .54); I <sup>2</sup> = 0%	0.75	1 A	1
Test for overall effect	ct: $Z = 4.39$	(P < .0	01)		0.75	1	1.5
					Favors BN shif	IT Favo tanalysis	ors EVT

15

**eFigure 12:** Forest plot presenting the association of EVT compared to BMT with reduced disability at 3 months (using the generalized OR), stratified by onset-to randomization time (<6 hours vs.  $\geq$  6 hours).


SE: standard error; CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment.



shift analysis

**eFigure 13:** Analysis of Safety Outcomes. Forest plot presenting the association of EVT compared to BMT with sICH (panel A), any-ICH (panel B) and 3-month mortality (panel C).

CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment; sICH: symptomatic intracranial hemorrhage; aICH: any intracranial hemorrhage.



Test for overall effect: Z = -0.28 (P = .78)



2

0.5


**eFigure 14:** Sensitivity analysis regarding the association of EVT compared to BMT with sICH, including the studies that reported this outcome up to 48 hours post intervention.<sup>8,10</sup>

CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment; sICH: symptomatic intracranial hemorrhage.

	EVT		вмт		Risk Ratio			Risk Ratio				
Study	Events	Total	Events	Total	Weight	IV, Random, 95% C	I IV, Random, 95% CI					
ANGEL-ASPECT	14	230	6	225	56.0%	2.28 [0.89, 5.83]						
RESCUE-Japan LIMIT	9	101	5	102	44.0%	1.82 [0.63, 5.24]		_				
Total (95% CI)		331		327	100.0%	2.06 [1.02, 4.17]	_					
Heterogeneity: Tau <sup>2</sup> = 0; (	0.2			-								
Test for overall effect: Z = 2.02 (P = .04)								0.5	1 2	5		
							Favors EVT Favors BMT sICH					


**eFigure 15:** Sensitivity analysis regarding the association of EVT compared to BMT with any ICH, including the studies that reported this outcome up to 48 hours post intervention.<sup>8,10</sup>

CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment; aICH: any intracranial hemorrhage.




eFigure 16: Forest plot presenting the association of EVT compared to BMT with sICH, stratified by the different definitions used by each study. The ANGEL-ASPECT trial<sup>8</sup> used the Heidelberg bleeding classification (NIHSS-score increase of  $\geq 4$  points or an increase in the score for an NIHSS subcategory of  $\geq 2$  points with any intracranial hemorrhage on imaging),<sup>11</sup> while the SELECT2,<sup>9</sup> RESCUE-Japan LIMIT,<sup>10</sup> and TESLA<sup>6,7</sup> trials used the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) definition (parenchymal hematoma type 2 and NIHSS-score increase by at least 4 points).<sup>12</sup>

CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment; sICH: symptomatic intracranial hemorrhage; SITS-MOST: Safe Implementation of Thrombolysis in Stroke-Monitoring Study.



eFigure 17: Sensitivity analysis regarding the association of EVT compared to BMT with reduced disability at 3 months, after excluding the ANGEL-ASPECT trial.<sup>8</sup>

SE: standard error; CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment.




**eFigure 18:** Sensitivity analysis regarding the association of EVT compared to BMT with independent ambulation at 3 months, after excluding the ANGEL-ASPECT trial.<sup>8</sup>

CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment; mRS: modified Rankin Scale.

	EVT		BMT			Risk Ratio	Risk Ratio		
Study	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI		
RESCUE-Japan LIMIT	31	100	13	102	18.0%	2.43 [1.35, 4.37]			
SELECT2	67	178	32	174	45.3%	2.05 [1.42, 2.95]			
TESLA	45	152	29	148	36.6%	1.51 [1.00, 2.27]			
Total (95% CI)		430		424	100.0%	1.89 [1.47, 2.43]	-		
Heterogeneity: Tau <sup>2</sup> = 0	.001; Chi <sup>2</sup>	² = 2.05	, df = 2 (P	= .36);	l <sup>2</sup> = 2%				
Test for overall effect: Z	= 4.97 (P	< .01)					0.5 1 2		
							Favors BMT Favors EVT mRS 0-3		


**eFigure 19:** Sensitivity analysis regarding the association of EVT compared to BMT with good functional outcome at 3 months, after excluding the ANGEL-ASPECT trial.<sup>8</sup>

CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment; mRS: modified Rankin Scale.




**eFigure 20:** Sensitivity analysis regarding the association of EVT compared to BMT with excellent functional outcome at 3 months, after excluding the ANGEL-ASPECT trial.<sup>8</sup>

CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment; mRS: modified Rankin Scale.



**eFigure 21:** Sensitivity analysis regarding the association of EVT compared to BMT with sICH, after excluding the ANGEL-ASPECT trial.<sup>8</sup>

CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment; sICH: symptomatic intracranial hemorrhage.



**eFigure 22:** Sensitivity analysis regarding the association of EVT compared to BMT with any ICH, after excluding the ANGEL-ASPECT trial.<sup>8</sup>

CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment; aICH: any intracranial hemorrhage.

	EVT		BMT		Risk Ratio			Risk Ratio				
Study	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI					
RESCUE-Japan LIMIT	58	101	32	102	31.5%	1.83 [1.31, 2.55]						
SELECT2	5	178	3	174	1.7%	1.63 [0.40, 6.71]				•		
TESLA	110	151	56	149	66.7%	1.94 [1.54, 2.44]				-		
Total (95% CI)		430		425	100.0%	1.90 [1.57, 2.29]				•		
Heterogeneity: Tau <sup>2</sup> = 0;		I										
Test for overall effect: Z = 6.72 (P < .01)								0.5	1	2	5	
							Favors EVT Favors BMT aICH					

**eFigure 23:** Sensitivity analysis regarding the association of EVT compared to BMT with mortality at 3 months, after excluding the ANGEL-ASPECT trial.<sup>8</sup>

CI: confidence interval; IV: inverse variance; EVT: endovascular treatment; BMT: best medical treatment.

